Results 221 to 230 of about 326,443 (336)

Trojan horses at leptomeningeal cellular gates: Antibody-drug conjugates deliver cytotoxic payloads. [PDF]

Med
Nikanjam M, Kurzrock R.
europepmc   +1 more source

127TiP An open-label, randomized, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO 01)

A. González-Martín, Jo Marie Tran Janco, June‐Yong Lee, Domenica Lorusso, Sven Mahner, K.N. Moore, D.S. Tan, Veronica Mariotti, Jared H. Hara, Shao‐Ying Hua, J.F. Liu, Kazuki Hasegawa   +11 more
openalex   +2 more sources

LAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER [PDF]

, 2015
Jamal Zekri, M.N. Mokhtar, S.M.M. Karim, Tarek Darwish, Meteb Al‐Foheidi, Amal Rizvi, Samah Soud Alrehaily, Mervat Mahrous, Mariam Mansour   +8 more
openalex   +1 more source

Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study

International Journal of Cancer, EarlyView.
What's New? This study evaluated patient characteristics and treatment strategies in stages II and III HR+/HER2− breast cancer. Neoadjuvant systemic therapy frequently facilitated breast‐conserving procedures and less invasive axillary surgery. Approximately half of the patients undergoing primary surgery received a mastectomy, and all with positive ...
Layla Andour, Judith R. Kroep, Hein Putter, Rob A. E. M. Tollenaar, Wilma E. Mesker, Marieke E. Straver   +5 more
wiley   +1 more source

Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China. [PDF]

Cancer Control
Zheng F, Zhang J, Zhou D, Ren G, Qiang L, Wang T, Pan F, Shan C, Xia C, Yang F, Wang H, Liu G, Wang J, Hua R, Du X, Zhang B, Li H.   +16 more
europepmc   +1 more source

Improving genetic diagnosis of hereditary tumor syndromes: From expanded gene panels to functional genomics

International Journal of Cancer, EarlyView.
Abstract Genetic tumor risk syndromes (genturis) contribute substantially to the overall cancer burden and provide opportunities for early detection, prevention, and individualized treatment. Yet, many affected individuals remain undiagnosed due to restrictive testing criteria and challenges in variant interpretation.
Mayra Sauer, Morghan C. Lucas, Vitus Prokosch, Thomas Keßler, Thomas Risch, Andreas Laner, Jan Henkel, Anna Benet‐Pagès, Ariane Hallermayr, Verena Steinke‐Lange, Elke Holinski‐Feder, Barbara Klink   +11 more
wiley   +1 more source

Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case. [PDF]

Front Immunol
Diao Y, Yin H, Sun X, Dong Q, Zhang J.
europepmc   +1 more source

Breast cancer incidence and survival by subtype, stage at diagnosis and socioeconomic deprivation among young women in the Community of Madrid, Spain

International Journal of Cancer, EarlyView.
What's New? Breast cancer comprises a heterogeneous group of diseases with differing features and survival outcomes. In particular, survival is affected by socioeconomic status, though age‐specific patterns remain unknown. Here, the authors examined differences in breast cancer incidence and survival specifically among young women in the Community of ...
Candela Pino‐Rosón, Sonia Ávila‐Arroyo, David Parra‐Blázquez, María J. Soto Zabalgogeazcoa, Daniel Moñino, Raquel López‐González, Clotilde Sevilla‐Hernández, Cristina González‐Blázquez, Miguel Martín, Nuria Aragonés   +9 more
wiley   +1 more source

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. [PDF]

Cancer Discov
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H.   +25 more
europepmc   +1 more source

HER2-Positive Breast Cancers Make More CXCR4 Which Helps Them Invade and Metastasize [PDF]

, 2004
na
openalex   +1 more source